TWIST1 and myelodysplastic syndrome: A more recent study by this same group found that TWIST1 expression was actually higher in MDS patients that were non-responsive to treatment with the DNA demethylating agent 5-aza-2’-deoxycytidine, compared to those that were responsive (144).